RT Journal Article
SR Electronic
T1 Update to coagulopathy in COVID-19: Manifestations and management
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
DO 10.3949/ccjm.87a.ccc024-up
A1 Simon R. Mucha
A1 Siddharth Dugar
A1 Keith McCrae
A1 Douglas Joseph
A1 John Bartholomew
A1 Gretchen L. Sacha
A1 Michael Militello
YR 2020
UL http://www.ccjm.org/content/early/2020/12/14/ccjm.87a.ccc024-up.abstract
AB Severe COVID-19 illness is associated with intense inflammation, leading to high rates of thrombotic complications that increase morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings of severe COVID-19–associated coagulopathy. Prophylaxis against venous thromboembolism is paramount for all hospitalized patients with COVID-19, with more aggressive prophylaxis and screening recommended for critically ill patients with D-dimer levels above 3.0 μg/mL. Point-of-care ultrasonography is the imaging method of choice for patients at high risk, as it entails minimal risk of exposing providers to the virus.